Author:
Shimabukuro-Vornhagen Alexander,Rothe Achim,Nogova Lucia,Kochanek Matthias,Scheid Christoph,von Bergwelt-Baildon Michael
Abstract
Abstract
Introduction
In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL
+ clone and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived from the BCR-ABL
+ clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders.
Case presentation
We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib.
Conclusion
This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL
+ chronic myeloid leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future studies using imatinib to treat patients with chronic myeloid leukemia.
Publisher
Springer Science and Business Media LLC
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献